To date, loop diuretics are the mainstay treatment for decongestion in patients with acute
decompensated heart failure (HF). In clinical practice, loop diuretics have also been utilized …

Background Heart failure (HF) is a common condition associated with substantial cost,
morbidity, and mortality. Because results of clinical trials in the acute decompensated heart …

Aim We aimed to study the relationships of loop diuretic dose with renal function and clinical
outcomes in patients with chronic heart failure (HF). Methods and results Loop diuretic dose …

Aims Guidelines recommend down‐titration of loop diuretics (LD) once euvolaemia is
achieved. In outpatients with heart failure (HF), we investigated LD dose changes in daily …

Abstract Purpose of Review Loop diuretics are the cornerstone of the treatment of
congestion in heart failure patients. The manuscript aims to summarize the most updated …

Background: Clinical evidence of the effects of loop diuretics in patients with heart failure
with preserved ejection fraction (HFpEF) is lacking. Thus, we compared the impact of …

Introduction This study aimed to evaluate the use and dose of loop diuretics (LDs) across the
entire ejection fraction (EF) spectrum in a large,'real-world'cohort of chronic heart failure (HF) …

Congestion is a major clinical sign of acute heart failure (AHF), and loop diuretics remain the
first-line treatment option for decongestion in the acute phase of the disease. 1 Even though …

Aims Furosemide, a short‐acting loop diuretic (SD), is the dominant agent prescribed for
heart failure (HF) in clinical practice. However, accumulating data suggests that long‐acting …

Although approaches to optimize volume status, such as modifying fluid and salt intake, are
important, 1 use of loop diuretics remains the mainstay of treatment for congestion in …